Haemonetics (HAE) has been banking on its growth drivers like the Plasma and Hospital business. New product launches also lead to market expansion. The stock carries a Zacks Rank #2 (Buy) currently. Major Factors Driving HAE Stock Haemonetics' Plasma business continues to grow, banking on an expanding end-user market for plasma-derived biopharmaceuticals. In the second quarter of 2024, U.S. collection volume growth was robust. Both North America software and Europe disposable revenues witnessed double-digit ...

NTLA-2002 Development and Clinical Trial - NTLA-2002 is a single-dose CRISPR-based gene editing therapy designed to treat hereditary angioedema (HAE) by inactivating the kallikrein B1 (KLKB1) gene, which encodes for prekallikrein, the kallikrein precursor protein [1][4] - The HAELO Phase 3 trial is a global, randomized, double-blind, placebo-controlled study involving 60 adults with Type I or Type II HAE, with patients randomized 2:1 to receive a single 50 mg infusion of NTLA-2002 or placebo [2] - The primary endpoint of the Phase 3 trial is the change in the number of HAE attacks from week 5 through week 28 [2] - Interim Phase 1 clinical data showed dramatic reductions in attack rates and consistent, deep, and durable reductions in kallikrein levels [3] Regulatory Designations and Potential Impact - NTLA-2002 has received five notable regulatory designations, including Orphan Drug and RMAT Designation by the U.S. FDA, Innovation Passport by the U.K. MHRA, PRIME Designation by the European Medicines Agency, and Orphan Drug Designation by the European Commission [4] - NTLA-2002 has the potential to become the first one-time treatment for HAE, addressing the real-world needs of patients, physicians, and payors [1][4] Hereditary Angioedema (HAE) Overview - HAE is a rare, genetic disease affecting approximately one in 50,000 people, characterized by severe, recurring, and unpredictable inflammatory attacks that can be life-threatening [5] - Current treatment options for HAE include lifelong therapies requiring chronic intravenous or subcutaneous administration, often with breakthrough attacks despite treatment [5] Intellia Therapeutics Overview - Intellia Therapeutics is a leading clinical-stage gene editing company focused on CRISPR-based therapies, with in vivo programs targeting disease-causing genes directly inside the human body and ex vivo programs for cancer and autoimmune diseases [6][7] - The company is advancing its modular gene editing platform, with NTLA-2002 being its second in vivo candidate to enter late-stage clinical development [1]

BOSTON, Oct. 3, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2025 financial results at 6:00 am ET on Thursday, November 7, 2024. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on November 7, 2024. The call can be accessed via teleconference at: Q2 2025 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will ...

ZUG, Switzerland, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced the acceptance of six abstracts, two for oral presentation and four for poster presentation, at the 2024 Global Angioedema Forum – HAEi Global Leadership Workshop, taking place in Copenhagen, Denmark, from Oct. 4-5, 2024. Details are as follows: Title: Long-Term ...

Haemonetics Corporation (HAE) is well-poised to grow in the coming quarters, backed by the strong potential of the Plasma franchise. The company's Hemostasis Management franchise is evolving and helping create new opportunities for growth and diversification. Strong financial stability also buoys optimism. Meanwhile, headwinds from adverse foreign exchange effects pose concern to Haemonetics' operations. In the past year, this Zacks Rank #2 (Buy) company has lost 14.5% against the industry's 24.6% growth an ...

First presentation of detailed Phase 2 results following previous positive topline announcement that study of NTLA-2002 met primary and all secondary endpoints Intellia to host investor webcast on Monday, October 28, at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that data from the Phase 2 study of NTLA-2002 will be pr ...

Extension data confirm the observed safety and tolerability profile from Phase 2 studies and further support the potential for deucrictibant to become a preferred therapy for the management of HAE Long-term prophylaxis extension data of deucrictibant shows attack reduction is maintained for over one year; open-label extension participants experienced a 93% reduction in attacks compared to baseline Long-term on-demand extension data of deucrictibant immediate-release capsule shows median onset of symptom rel ...

Haemonetics (HAE) has been on a downward spiral lately with significant selling pressure. After declining 15.9% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier. Guide to Identifying Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock ...

Haemonetics Corporation (HAE) recently announced the full market release of its VASCADE MVP XL — a mid-bore venous closure system. The VASCADE MVP XL system will now be available to U.S. hospitals as the newest addition to the company's VASCADE portfolio of vascular closure systems. With the full market release underway and an ongoing clinical trial program, the company is well-positioned to broaden the indications for the VASCADE MVP XL system to even larger access points. The latest development is expecte ...

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro. Here's the latest list of major oversold player ...